Icatibant Axiromed (Icatibant)

Icatibant blocks the bradykinin B2 receptor on blood vessels, stopping bradykinin‑induced vasodilation and increased permeability. This inhibition limits fluid leakage into tissues, thereby reducing the swelling characteristic of HAE attacks.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, severity of the attack, and regulatory guidelines. The medication is administered as a subcutaneous injection according to the prescriber’s instructions.

The safety of icatibant in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a selective bradykinin B2 receptor antagonist, whereas other options such as C1‑esterase inhibitors replace a deficient protein. Icatibant offers rapid subcutaneous administration and direct blockade of the bradykinin pathway, making it useful for patients who prefer a self‑injectable option.

Icatibant Axiromed should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial to maintain stability.

Icatibant is given as a single subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and paradoxical worsening of angioedema. Patients should be monitored for signs of allergic reaction and instructed to seek immediate medical attention if severe symptoms develop.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients receiving ACE inhibitors or other agents that increase bradykinin levels, and it should be avoided in those with uncontrolled severe cardiovascular disease.